tetano
Editor, Senior Moderator
Hematol Rep
. 2024 Jul 29;16(3):504-511.
doi: 10.3390/hematolrep16030048. Persistently High Platelet Factor 4 Levels in an Adolescent with Recurrent Late Thrombotic Complications after SARS-CoV-2 mRNA Vaccination
Yoichi Haga[SUP] 1 [/SUP], Akira Ohara[SUP] 1 [/SUP], Tsuneyoshi Yakuwa[SUP] 2 [/SUP], Akari Yamashita[SUP] 1 [/SUP], Midori Udo[SUP] 1 [/SUP], Masaki Matsuoka[SUP] 1 [/SUP], Hiroshi Ohara[SUP] 3 [/SUP], Atsushi Yasumoto[SUP] 4 [/SUP], Hiroyuki Takahashi[SUP] 1 [/SUP]
Affiliations
Thrombosis after severe acute respiratory syndrome coronavirus 2 vaccination is a serious complication in patients with a thrombophilic predisposition. Herein, we present a 17-year-old female who had underlying antiphospholipid syndrome (APS) and developed deep vein thrombosis (DVT) 6 months after her second BNT162b2 vaccine dose. Although she had no family history of thrombosis, she had previously developed DVT at 6 years of age, with thrombus formation in the right common iliac vein and the inferior vena cava, along with concomitant left pulmonary infarction. The patient had received anticoagulant therapy for 6 years after DVT onset, with subsequent treatment cessation for 5 years without recurrence. She received the BNT162b2 vaccine at 17 years of age, 1 week before a routine outpatient visit. Platelet factor 4 elevation was detected 14 days after the first vaccination, persisting for 5 months without thrombotic symptoms. Six months after the second vaccine dose, the DVT recurred and was treated with a direct oral anticoagulant. The vaccine was hypothesized to exacerbate the patient's APS by activating coagulation. Platelet factor 4 levels may indicate coagulation status. When patients predisposed to thrombosis are vaccinated, coagulation status and platelet activation markers should be monitored to prevent DVT development.
Keywords: SARS-CoV-2 vaccine; anticoagulants; antiphospholipid antibody syndrome; platelet factor 4; venous thrombosis.
. 2024 Jul 29;16(3):504-511.
doi: 10.3390/hematolrep16030048. Persistently High Platelet Factor 4 Levels in an Adolescent with Recurrent Late Thrombotic Complications after SARS-CoV-2 mRNA Vaccination
Yoichi Haga[SUP] 1 [/SUP], Akira Ohara[SUP] 1 [/SUP], Tsuneyoshi Yakuwa[SUP] 2 [/SUP], Akari Yamashita[SUP] 1 [/SUP], Midori Udo[SUP] 1 [/SUP], Masaki Matsuoka[SUP] 1 [/SUP], Hiroshi Ohara[SUP] 3 [/SUP], Atsushi Yasumoto[SUP] 4 [/SUP], Hiroyuki Takahashi[SUP] 1 [/SUP]
Affiliations
- PMID: 39189244
- PMCID: PMC11348110
- DOI: 10.3390/hematolrep16030048
Thrombosis after severe acute respiratory syndrome coronavirus 2 vaccination is a serious complication in patients with a thrombophilic predisposition. Herein, we present a 17-year-old female who had underlying antiphospholipid syndrome (APS) and developed deep vein thrombosis (DVT) 6 months after her second BNT162b2 vaccine dose. Although she had no family history of thrombosis, she had previously developed DVT at 6 years of age, with thrombus formation in the right common iliac vein and the inferior vena cava, along with concomitant left pulmonary infarction. The patient had received anticoagulant therapy for 6 years after DVT onset, with subsequent treatment cessation for 5 years without recurrence. She received the BNT162b2 vaccine at 17 years of age, 1 week before a routine outpatient visit. Platelet factor 4 elevation was detected 14 days after the first vaccination, persisting for 5 months without thrombotic symptoms. Six months after the second vaccine dose, the DVT recurred and was treated with a direct oral anticoagulant. The vaccine was hypothesized to exacerbate the patient's APS by activating coagulation. Platelet factor 4 levels may indicate coagulation status. When patients predisposed to thrombosis are vaccinated, coagulation status and platelet activation markers should be monitored to prevent DVT development.
Keywords: SARS-CoV-2 vaccine; anticoagulants; antiphospholipid antibody syndrome; platelet factor 4; venous thrombosis.